Prostate Cancer Clinical Trial
Official title:
Effects of NMDA-Receptor Antagonism on Hyperalgesia, Opioid Use, and Pain After Radical Prostatectomy in Young and Elderly Patients
The primary aim is to determine whether perioperative NMDA-receptor antagonism has
differential effects on postoperative pain, hyperalgesia and morbidity in younger and older
patients. In order to achieve this aim, the researchers propose to conduct the first
randomized, double-blind placebo-controlled study designed to investigate age differences in
the effects of perioperative oral administration of an NMDA-receptor antagonist (amantadine)
in men undergoing radical prostatectomy. In addition, age differences in psychosocial
factors and the pharmacological properties of amantadine and morphine will be measured to
control for, and clarify, their contribution to the differences found.
The specific objectives of the study are to:
1. investigate the effects of perioperative NMDA receptor blockade on postoperative
hyperalgesia, pain and analgesic consumption in young and elderly men
2. assess age differences in the intensity and course of secondary hyperalgesia after
surgery
The immediate postoperative period is associated with spontaneous pain and hyperalgesia,
i.e., increased pain response (both intensity and duration) to normally painful stimuli
following tissue injury or damage.
The development and maintenance of secondary hyperalgesia depend on complex plastic changes
in spinal cord dorsal horn cells after peripheral injury or damage. Afferent impulses
signaling the damage are carried to the dorsal horn by slowly conducting, unmyelinated
C-fibres. C-fibres release glutamate which acts at three receptor types: metabotropic,
kainate/AMPA and NMDA. NMDA receptor activation, through a complex cascade of intracellular
events, results in dorsal horn neuron hyperexcitability or central sensitization. These
cells have increased spontaneous activity, decreased threshold, increased response to
afferent input, prolonged afterdischarge to repeated stimulation, and an expansion of
receptive fields. Central sensitization is expressed behaviorally as secondary hyperalgesia
and contributes to prolonged postoperative pain. It also may trigger pathological
reorganization of neural circuitry leading to the development of chronic postsurgical pain.
Through these processes, tissue injury may have profound effects on the CNS that long
outlast the injury.
In animal models of pain, NMDA agonists induce central sensitization and hyperalgesia
whereas antagonists decrease or prevent hyperalgesia. In humans, NMDA-receptor antagonism
decreases secondary hyperalgesia subsequent to experimentally-induced pain.
Perioperative administration of NMDA antagonists, that is, before, during and after surgery,
may be the ideal intervention to block the initiation and maintenance of central
sensitization. Several studies have found that this intervention reduces postoperative
hyperalgesia, pain, and analgesic use; however, others have not found these effects. This is
not surprising given the variability across studies in factors such as surgical procedure,
extent and nature of tissue damage, duration of surgery, pharmacokinetics of the agent(s)
tested, and intraoperative and postoperative analgesia. Nonetheless, the weight of the
evidence suggests that preventing or minimizing central sensitization reduces pain and
analgesic requirements.
Co-administration of NMDA antagonists and opioids has been advocated as an effective
approach. The combination of morphine and amantadine should reduce postoperative pain by
inducing analgesia through actions on opioid-mediated receptor systems and by reducing
hyperalgesia via NMDA receptor-mediated events . The combination also should produce fewer
opioid-related adverse effects due to the anticipated opioid-sparing effect. The present
proposal describes the first direct comparison of perioperative NMDA receptor blockade
coupled with intra- and post-operative opioid administration in young and elderly patients.
In order to minimize the influence of other perioperative factors on the outcome variables,
all patients will undergo the same surgical procedure and anesthetic protocol. Furthermore,
factors that cannot readily be standardized (e.g., surgical duration, mood) will be measured
and controlled for statistically. This increases the internal validity of the proposed study
and our ability to detect age and drug effects.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |